ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Prospective Comparison of PET Imaging with PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.European radiology · 2026Article
- Interobserver and intraobserver agreement for equivocal lesions in Ga-68 PSMA PET/CT according to PSMA-RADS 2.0 criteria.Annals of nuclear medicine · 2026Article
- PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.Abdominal radiology (New York) · 2026Review
- Review
- Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions.Medical review (2021) · 2025Review
- Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.Radiology. Imaging cancer · 2025Article
- Rate of unspecific bone uptake on PSMA PET is determined by the Scaffold - not the Radionuclide. Letter regarding: "The homunculus of unspecific bone uptakes associated with PSMA- targeted tracers: a systematic review-based definition" and "Cutting back on overdiagnosis - Occam's razor and unspecific bone uptakes in PSMA PET".European journal of nuclear medicine and molecular imaging · 2024Article
- Article
- PSMA PET imaging in the diagnosis and management of prostate cancer.Abdominal radiology (New York) · 2023Review
- Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.European urology · 2023Article
- Predicting Outcomes of Indeterminate Bone Lesions onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.Life (Basel, Switzerland) · 2023Review
- Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified onTomography (Ann Arbor, Mich.) · 2022Article
- Comparing the clinical performance and cost efficacy of [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- Clinical insignificance of [European journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Prostate-specific membrane antigen (PSMA)-targeted PET imaging has become commonly used in patients with prostate cancer (PCa). The PSMA reporting and data system version 1.0 (PSMA-RADS version 1.0) categorizes lesions on the basis of the likelihood of PCa involvement, with PSMA-RADS-3A (soft-tissue) and PSMA-RADS-3B (bone) lesions being indeterminate for the presence of disease. We retrospectively reviewed the imaging follow-up of such lesions to determine the rate at which they underwent changes suggestive of underlying PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.